Loading...

TARA PROTARA THERAPEUTICS INC Product Launches 8-K Filing

PRTR

TR

PROTARA THERAPEUTICS INC

(TARA)

2025 8-K

Stock Offering Details

Investor Update

Investor Presentation Released

Financial Results Report

Financial Statements

Financial Results

Clinical Trial Update

Financial Results

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Private Placement

Resignation of Chief Medica...

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

FDA Clearance for Phase 2 T...

Positive Preliminary Data A...

Disclosure of Cash Holdings...

Financial Results Announcement

Appointment of CFO

Corporate Presentation

External Links:

On November 19, 2025, Protara Therapeutics, Inc. announced interim results from its Phase 2 STARBORN-1 clinical trial for TARA-002, with 80% of treated patients achieving clinical success. This event highlights potential advancements in treating pediatric lymphatic malformations.

AI Assistant

PROTARA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.